Is Sermorelin Legal in Washington State? A Woman's Complete Guide

What Sermorelin Actually Is (and Why the Legal Category Matters for Women)

Sermorelin is a synthetic 29-amino-acid peptide analog of growth-hormone-releasing hormone (GHRH). It tells your pituitary to release your own growth hormone rather than supplying exogenous GH directly. That mechanism is clinically meaningful for women because growth hormone secretion declines with age alongside estrogen, and perimenopausal women experience a sharper drop in pulsatile GH amplitude than men of the same age, according to data published in the Journal of Clinical Endocrinology and Metabolism.

That sex-specific decline is one reason clinicians writing prescriptions for sermorelin see a disproportionate number of perimenopausal and postmenopausal women in their practices.

Understanding the legal framework before you ask your provider for a prescription protects you from two real risks: receiving a product from a non-compliant source, or misunderstanding why a pharmacy requires a written, patient-specific script.

Sermorelin Is Not the Same as Growth Hormone

Growth hormone (somatropin) is an FDA-approved drug with specific labeled indications and tight prescribing rules. Sermorelin is a secretagogue: it stimulates rather than replaces. Because it acts indirectly, the regulatory pathway differs, and that matters when you are researching whether a Washington clinician can legally write you a prescription.

The FDA Approval Status Explained Plainly

Sermorelin acetate was once marketed as Geref (Serono) for pediatric growth hormone deficiency. That brand was voluntarily withdrawn from the U.S. Market in 2008 for commercial, not safety, reasons. The withdrawal means no currently FDA-approved finished-drug version of sermorelin exists. It does not mean the substance is banned. The FDA's list of bulk drug substances that may be used in compounding under 503A does not include sermorelin as a prohibited substance, which allows licensed compounding pharmacies to prepare it when a valid prescription exists.

The Federal Legal Framework: 503A vs. 503B and Why It Matters to You

The Compounding Quality Act of 2013 created two categories of compounding pharmacy. Your sermorelin prescription will almost certainly route through a 503A pharmacy.

503A Pharmacies: Patient-Specific Compounding

A 503A pharmacy operates under state pharmacy board oversight and compounds drugs in response to individual prescriptions. Your Washington-licensed provider writes a script with your name on it. The pharmacy prepares that specific batch for you. Because sermorelin is not on the FDA's categorical prohibition list for 503A bulk substances, a 503A pharmacy in Washington may legally compound and dispense it under these conditions.

The prescription must be:

• Written by a practitioner licensed in Washington State
• Patient-specific (your name, your dose, your formulation)
• Dispensed by a pharmacy licensed by the Washington State Department of Health Pharmacy Quality Assurance Commission

503B Outsourcing Facilities: Not the Right Route for Sermorelin

503B facilities may compound without a patient-specific prescription but must use only FDA-approved finished drugs or substances on the 503B-approved bulk list. Sermorelin does not currently appear on the 503B-approved bulk substance list, which means 503B outsourcing facilities cannot legally compound it. If you see sermorelin being sold in bulk or without a prescription through a 503B-listed facility, that is a compliance red flag.

What "Not FDA-Approved" Does Not Mean

This phrase causes unnecessary alarm. Hundreds of compounded medications women use regularly, including bioidentical estradiol vaginal preparations, progesterone capsules in specific doses, and low-dose naltrexone, share this status. The absence of a finished-drug approval does not equal illegality when federal compounding law permits patient-specific preparation. The critical distinction is whether the substance is on a prohibited list. As of the date this article was reviewed, sermorelin is not.

Washington State-Specific Rules

Washington State does not have a separate law banning sermorelin. The state's legal framework defers to the federal 503A compounding structure and adds its own pharmacy board oversight layer.

The Washington State Pharmacy Quality Assurance Commission

The Washington State Pharmacy Quality Assurance Commission (PQAC) licenses and inspects all pharmacies operating within or shipping into Washington. A compounding pharmacy preparing sermorelin for a Washington patient must hold an active PQAC license. If you are working with an out-of-state compounding pharmacy, that pharmacy must be licensed to ship into Washington, which requires PQAC non-resident pharmacy registration.

Checking your pharmacy's PQAC license status is straightforward: the Washington Department of Health maintains a public license lookup tool. If the pharmacy cannot produce a current Washington license or non-resident registration, do not use it.

Washington Medical Practice Act and Prescribing Authority

Washington's Medical Practice Act (RCW Title 18) permits licensed MDs, DOs, advanced registered nurse practitioners (ARNPs), and physician assistants (PAs) to prescribe compounded preparations when medically indicated. There is no Washington-specific carve-out prohibiting sermorelin prescriptions. The standard of care requirement applies: the prescribing clinician must conduct a proper evaluation, document a clinical rationale, and maintain a legitimate patient-provider relationship, including an appropriate examination (in-person or via telehealth under Washington's telehealth standards).

Telehealth and Sermorelin in Washington

Washington State has broad telehealth parity law requiring insurers to cover telehealth services comparably to in-person care. Clinicians practicing telehealth in Washington must hold a Washington license. A telehealth visit is a valid basis for a sermorelin prescription as long as the evaluation meets the standard of care, which means a clinical history, symptom review, and baseline labs before prescribing.

How Women Get a Legal Sermorelin Prescription in Washington

The practical pathway involves three steps. Each step has a women's-health-specific consideration.

Step 1: Baseline Lab Work

Before any prescription is written, a responsible clinician orders baseline labs. For women, the minimum meaningful panel includes:

• IGF-1 (Insulin-Like Growth Factor 1): The primary marker of GH axis function. Reference ranges are age- and sex-specific. A 45-year-old perimenopausal woman has a different expected IGF-1 range than a 30-year-old in the follicular phase.
• Fasting glucose and HbA1c: Sermorelin can transiently raise blood glucose. Women with PCOS, who already carry elevated insulin resistance risk, need this baseline documented before starting.
• Thyroid panel (TSH, free T4): Hypothyroidism blunts the GH response to GHRH stimulation. Unmanaged thyroid disease will undermine sermorelin's effect, and postpartum thyroiditis is common enough that any postpartum woman being evaluated should have thyroid function confirmed.
• Sex hormones (estradiol, FSH, LH): Relevant because estrogen status independently modulates GH secretion and IGF-1 interpretation. A woman on oral estrogen therapy has suppressed IGF-1 due to hepatic first-pass effects, as documented in studies of oral versus transdermal estrogen and the GH axis. Transdermal estrogen does not produce the same IGF-1 suppression, so the route of hormone therapy changes how you interpret her IGF-1 result.
• Prolactin: Elevated in conditions like prolactinoma, which can co-exist with GH axis disruption.

Step 2: Clinical Evaluation and Diagnosis

A Washington-licensed clinician reviews your history and labs. The clinical rationale for sermorelin in women typically includes one or more of the following:

• Confirmed low or low-normal IGF-1 relative to age-matched and hormonal-status-matched reference ranges
• Symptoms of GH decline: disrupted sleep architecture, decreased lean mass, increased central adiposity, fatigue, and reduced recovery from exercise
• Perimenopause or postmenopause with GH-related metabolic concerns
• Consideration of PCOS: women with PCOS have altered GH secretory patterns, with some research showing blunted GH pulses and elevated GH pulse frequency dysregulation, though the evidence for sermorelin specifically in PCOS is limited and extrapolated rather than directly studied in randomized trials

The clinician documents the indication. Without documented clinical rationale, the prescription does not meet the standard of care and may not be filled by a reputable compounding pharmacy.

Step 3: Prescription and Pharmacy Dispensing

The prescription specifies dose, concentration, formulation (typically lyophilized powder for reconstitution, injected subcutaneously), frequency, and quantity. You receive the compounded sermorelin from a PQAC-licensed pharmacy. You do not pick it up from a shelf. It is prepared for you specifically.

The WomanRx Three-Check Pharmacy Verification Framework for Compounded Sermorelin in Washington:

1. Confirm the pharmacy holds an active Washington PQAC license or non-resident registration (searchable at doh.wa.gov).
2. Confirm the pharmacy is PCAB-accredited or follows USP 797 sterile compounding standards, which Washington State requires for injectable preparations.
3. Confirm the prescription was written by a Washington-licensed clinician who conducted a documented clinical evaluation, not a questionnaire alone.

Any compounded sermorelin sold without a patient-specific prescription, or shipped from a pharmacy that cannot document Washington licensure, is operating outside the legal framework.

How Sermorelin Works Differently Across Female Life Stages

Sex-specific physiology shapes both the rationale for sermorelin and the expected response. This is not a minor caveat. It changes dosing logic, monitoring, and how you interpret your IGF-1 trend.

Reproductive Years (Ages 18 to 40)

Women in their reproductive years have naturally higher baseline GH pulse amplitude than postmenopausal women, in part because of estrogen's stimulatory effect on GH secretion. Sermorelin is less commonly indicated in this life stage unless there is documented GH axis dysfunction. The evidence base for routine use in healthy young women is thin. Clinicians should state this plainly: using sermorelin in a 25-year-old without documented IGF-1 deficiency is extrapolation, not evidence-based prescribing.

Trying to Conceive

Sermorelin is contraindicated if you are actively trying to conceive or planning pregnancy in the near term. See the pregnancy section below for details.

Perimenopause (Typically Ages 40 to 52)

This is the life stage where the evidence rationale for sermorelin in women is strongest. Estrogen begins fluctuating and declining. GH pulse amplitude drops concurrently. Research by Veldhuis and colleagues published in the Journal of Clinical Endocrinology and Metabolism showed that GH secretion in perimenopausal women declines significantly faster than in age-matched men over the same interval. Sleep disruption, common in perimenopause, further blunts the nocturnal GH surge that depends on slow-wave sleep. Sermorelin, taken at bedtime, is timed to amplify that nocturnal pulse.

Women on menopausal hormone therapy should tell their clinician whether they are using oral or transdermal estrogen, as the route changes IGF-1 interpretation. A study in the Journal of Clinical Endocrinology and Metabolism confirmed that oral estradiol suppresses hepatic IGF-1 production via first-pass metabolism while transdermal estradiol does not produce the same effect.

Postmenopause

In postmenopausal women, the GH-IGF-1 axis is measurably reduced. The data from randomized trials in this group remain limited, and most conclusions are drawn from studies that included both men and women without sex-stratified analysis. Clinicians should tell postmenopausal patients that the published evidence is extrapolated in significant part from male or mixed-sex cohorts, and that female-specific data from long-duration trials is an acknowledged gap.

Postpartum

Postpartum women are not candidates for sermorelin. The combination of unknown lactation safety, hormonal flux during recovery, and the physiological GH axis recalibration occurring after delivery makes the risk-benefit calculation unfavorable. Any postpartum woman who used sermorelin before or during early pregnancy should not resume it until she has finished breastfeeding and had a full clinical reassessment.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

This section is mandatory reading before you accept a sermorelin prescription.

Pregnancy

Sermorelin is contraindicated during pregnancy. No adequate human studies exist. Animal reproduction studies are not available in the public literature at a level that would establish safety. Because GH-axis signaling participates in fetal growth regulation, any exogenous manipulation of this axis during pregnancy carries theoretical fetal risk. The FDA has not assigned a formal pregnancy category to sermorelin given its compounded status, but absence of a category does not imply safety.

If you are pregnant or think you might be, stop sermorelin immediately and contact your obstetric provider.

Contraception Requirement

If you are of reproductive age and sexually active with the possibility of pregnancy, you need reliable contraception while using sermorelin. Discuss contraception options with your clinician before the first injection. This is not optional fine print. It is a clinical safety requirement.

Lactation

No human data on sermorelin transfer into breast milk exists. Peptides are generally considered to have low oral bioavailability if ingested by an infant, which might suggest low risk, but "might suggest" is not the same as established safety. Until specific lactation transfer studies are published, the standard clinical recommendation is to avoid sermorelin during breastfeeding. If you are breastfeeding and want to discuss GH-axis support, work with your provider on non-pharmacological approaches until weaning is complete.

Who Sermorelin Is Right For (and Who It Is Not)

Not every woman who wants sermorelin is a good candidate. Being specific about this protects you from financial and medical harm.

Women Who May Be Appropriate Candidates

• Perimenopausal or postmenopausal women with IGF-1 below the age-specific reference range and symptoms of GH decline (disrupted sleep, reduced lean mass, fatigue)
• Women with documented adult GH deficiency following pituitary surgery or radiation
• Women whose obesity medicine clinician is using it as an adjunct to a comprehensive metabolic program, with documented baseline and monitoring labs
• Women already stable on menopausal hormone therapy who want to address residual GH-axis symptoms not resolved by estrogen and progesterone alone

Women Who Are Not Appropriate Candidates

• Pregnant women or those planning pregnancy imminently
• Breastfeeding women
• Women with active malignancy or a personal history of hormone-sensitive cancer (the GH-IGF-1 axis has mitogenic activity; the risk in this population has not been adequately studied)
• Women with uncontrolled diabetes or insulin resistance without concurrent metabolic management, given sermorelin's transient glucose-raising effect
• Women with untreated hypothyroidism, which blunts the GH response and should be corrected first
• Women with normal IGF-1 for their age who are seeking anti-aging benefits without documented deficiency; the evidence does not support this use, and clinicians who prescribe without documented deficiency are not meeting the standard of care

The Evidence Gap Women Deserve to Hear

Women have historically been under-represented in GH axis clinical trials. Most foundational dosing and safety data for GHRH analogs come from studies that enrolled predominantly male subjects or did not stratify results by sex. What that means practically:

• Dosing recommendations for sermorelin in women are largely extrapolated from male data or from small mixed-sex studies.
• Long-term safety data specific to women, particularly women on concurrent hormone therapy, is not available from large randomized controlled trials.
• The effect of sermorelin on menstrual cycle regularity, endogenous sex hormone levels, and female-pattern body composition over periods exceeding 12 months has not been published in a well-powered randomized trial.

A 2020 systematic review in Endocrine Reviews examining GH secretagogues noted that sex-stratified analysis remained absent from most published trials, and called for female-specific pharmacokinetic studies. Any clinician who presents sermorelin to you as a fully characterized intervention in women is overstating the evidence.

This honesty is not a reason to dismiss sermorelin if your clinical picture supports its use. It is a reason to work with a clinician who monitors your IGF-1, glucose, and symptoms at 3-month intervals and who adjusts or stops treatment based on your individual response.

What to Expect From a Legitimate Washington Sermorelin Prescription

A compliant sermorelin prescription in Washington produces a specific clinical experience. Here is what the process should look like so you can recognize if something is off.

Your provider orders baseline labs before prescribing. The prescription specifies your name, dose in micrograms, the formulation, frequency (typically nightly), and a defined supply quantity (often 30 to 90 days). The pharmacy contacts you with reconstitution and injection instructions. You return for a follow-up lab draw at 8 to 12 weeks to check IGF-1 and fasting glucose. Your clinician reviews the results and adjusts dose or confirms continuation.

Guidelines from the American Association of Clinical Endocrinology support the practice of titrating GH-related therapies to bring IGF-1 into the middle of the age-appropriate reference range rather than to the top of the range, because supraphysiologic IGF-1 levels are associated with adverse metabolic and oncologic signals.

If a provider offers you sermorelin without labs, without follow-up, or based on a symptom questionnaire alone, that is not compliant prescribing under Washington's standard of care.

Common Questions About Sermorelin and Washington Law